Joel Greenblatt’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Joel Greenblatt’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-19,627	Closed	-$449K	–	1089
2018 Q1	$449K	Buy	19,627 +4,097	+26%	+$91.1K	0.01%	732
2017 Q4	$402K	Buy	+15,530	New	+$313K	0.01%	761
2015 Q4	–	Sell	-12,367	Closed	-$232K	–	1039
2015 Q3	$232K	Buy	+12,367	New	+$210K	﹤0.01%	838

Other funds holding CNCE

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Joel Greenblatt's CNCE Position: Q2 2018 in Review

Joel Greenblatt sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 19,627 shares — an estimated $449K sold.

Joel Greenblatt first reported a position in CNCE in Q3 2015 and held it in 3 quarters. The position peaked at $449K in Q1 2018. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

Joel Greenblatt reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Joel Greenblatt sold 19,627 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $449K.
Joel Greenblatt first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
Joel Greenblatt's Concert Pharmaceuticals, Inc. position peaked at $449K in Q1 2018.
120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Gotham Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.